We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics.
- Authors
Rodby, Roger A.; Rohde, Richard D.; Clarke, William R.; Hunsicker, Lawrence G.; Anzalone, Deborah A.; Atkins, Robert C.; Ritz, Eberhard; Lewis, Edmund J.
- Abstract
Background. Diabetic nephropathy is the most common cause of end-stage renal disease in the developed world. Angiotensin-converting enzyme inhibitors have been demonstrated to be renoprotective in type I diabetes and are now the standard of care for both hypertensive and non-hypertensive type I diabetic patients with any level of proteinuria. The role of blockade of the renin–angiotensin system in type II diabetic patients is not defined. The Collaborative Study Group has initiated the Irbesartan Type II Diabetic Nephropathy Trial (IDNT), studying the effect of the angiotensin II receptor antagonist irbesartan on progression of renal disease and mortality in type II diabetic patients with overt nephropathy and hypertension. Here we report the study design and baseline patient characteristics.
- Publication
Nephrology Dialysis Transplantation, 2000, Vol 15, Issue 4, p487
- ISSN
0931-0509
- Publication type
Article
- DOI
10.1093/ndt/15.4.487